Clinical Trial Results: Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis [Phase 3]

View source ↗

Summary

Phase III study of SAR302503 in intermediate-2 and high-risk myelofibrosis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• SAR302503

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hematopoietic Neoplasm | Phase 3 | Status: TERMINATED | Results posted: 2026-08-11